pentoxifylline has been researched along with HIV Coinfection in 20 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a single-arm, open-label pilot trial of the anti-inflammatory drug pentoxifylline to reduce systemic inflammation and improve endothelial function, measured by flow-mediated dilation of the brachial artery, in HIV-infected patients not requiring antiretroviral therapy." | 3.76 | Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study. ( Clauss, M; Desta, Z; Dubé, MP; Gupta, SK; Johnson, RM; Mather, KJ; Rehman, J; Saha, C, 2010) |
| "Our purpose was to assess the clinical efficacy of pentoxifylline in the treatment of pruritus in HIV-infected patients with PPE while measuring its effects on HIV viral load and levels of serum triglycerides, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-4." | 3.70 | Efficacy of pentoxifylline in the treatment of pruritic papular eruption of HIV-infected persons. ( Berman, B; Burke, G; Flores, F, 1998) |
| "The causes of pruritus are numerous including xerosis, drug and photoeruptions, follicular and papular eruptions as well as infestations and infections by a wide range of organisms." | 2.68 | Pruritus in HIV-1 disease: therapy with drugs which may modulate the pattern of immune dysregulation. ( Lee, RB; Skelton, HG; Smith, KJ; Wagner, KF; Yeager, J, 1997) |
| "Pentoxifylline (PTX) is a methylxanthine derivative with a variety of anti-inflammatory effects." | 2.44 | Pentoxifylline: a drug with wide spectrum applications in dermatology. ( Zargari, O, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (50.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 3 (15.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, SK | 3 |
| Mi, D | 1 |
| Dubé, MP | 3 |
| Saha, CK | 1 |
| Johnson, RM | 2 |
| Stein, JH | 2 |
| Clauss, MA | 2 |
| Mather, KJ | 2 |
| Desta, Z | 2 |
| Liu, Z | 2 |
| Zargari, O | 1 |
| Kucherov, II | 1 |
| Rytik, PG | 1 |
| Podol'skaya, IA | 1 |
| Mistryukova, LO | 1 |
| Korjev, MO | 1 |
| Clauss, M | 1 |
| Rehman, J | 1 |
| Saha, C | 1 |
| Wanchu, A | 3 |
| Bhatnagar, A | 3 |
| Kumar, B | 1 |
| Bambery, P | 3 |
| Singh, S | 3 |
| Lanzafame, M | 1 |
| Faggian, F | 1 |
| Lattuada, E | 1 |
| Antolini, D | 1 |
| Concia, E | 1 |
| Sathe, SS | 1 |
| Tsigler, D | 1 |
| Sarai, A | 1 |
| Kumar, P | 1 |
| Sadun, AA | 1 |
| Petrovich, MS | 1 |
| Madigan, MC | 1 |
| Balázs, C | 1 |
| Kiss, E | 1 |
| Mole, L | 1 |
| Margolis, D | 1 |
| Ghotbi, L | 1 |
| Holodniy, M | 1 |
| Dezube, BJ | 2 |
| Lederman, MM | 1 |
| Blanch Falp, J | 1 |
| García Pont, X | 1 |
| Torne Cachot, J | 1 |
| Moner Coromina, L | 1 |
| Baucells Azcona, JM | 1 |
| Smith, KJ | 1 |
| Skelton, HG | 1 |
| Yeager, J | 1 |
| Lee, RB | 1 |
| Wagner, KF | 1 |
| Berman, B | 1 |
| Flores, F | 1 |
| Burke, G | 1 |
| Wallis, RS | 1 |
| Johnson, JL | 1 |
| Okwera, A | 1 |
| Nsubuga, P | 1 |
| Whalen, CC | 1 |
| Mugerwa, RD | 1 |
| Ellner, JJ | 1 |
| Merino, E | 1 |
| Torrux, D | 1 |
| Boix, V | 1 |
| Portilla, J | 1 |
| Khullar, M | 1 |
| Sud, A | 2 |
| Arora, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo-Controlled Trial of Pentoxifylline to Improve Endothelial Function in HIV-Infected Patients Not Requiring Antiretroviral Therapy[NCT00796822] | Phase 2 | 26 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata: a Clinical and Dermoscopic Study.[NCT06087796] | Phase 1 | 60 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Flow-mediated dilation is nn in vivo measure of arterial endothelial function. We assessed changes in flow-mediated dilation from baseline to week 8. (NCT00796822)
Timeframe: Measured at baseline and Week 8
| Intervention | absolute percentage (Mean) |
|---|---|
| Pentoxifylline | -1.93 |
| Placebo | -1.06 |
Measure of systemic inflammation (NCT00796822)
Timeframe: Measured at baseline and Week 8
| Intervention | pg/mL (Mean) |
|---|---|
| Pentoxifylline | 65.9 |
| Placebo | -83.2 |
5 reviews available for pentoxifylline and HIV Coinfection
| Article | Year |
|---|---|
Pentoxifylline: a drug with wide spectrum applications in dermatology.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Behcet Syndrome; C | 2008 |
Novel inhibitors of HIV discovered among existing classes of pharmaceutical compounds indicated for unrelated clinical indications.
Topics: Animals; Anti-HIV Agents; Drug Combinations; Ferrous Compounds; HIV Infections; Humans; Mucins; Pent | 2009 |
Immunological aspects of the effect of pentoxifylline (Trental) (a brief review).
Topics: Animals; Cytokines; HIV Infections; Humans; Immune System; In Vitro Techniques; Neoplasms; Pentoxify | 1994 |
Pentoxifylline for the treatment of infection with human immunodeficiency virus.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; Cell Line; Clinical Trials as Topic; Drug Evaluation; | 1994 |
Pentoxifylline for the treatment of HIV infection and its complications.
Topics: Animals; HIV Infections; Humans; Pentoxifylline; Phosphodiesterase Inhibitors; Tumor Necrosis Factor | 1995 |
6 trials available for pentoxifylline and HIV Coinfection
| Article | Year |
|---|---|
Pentoxifylline, inflammation, and endothelial function in HIV-infected persons: a randomized, placebo-controlled trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Biomarkers; Endothelium, Vascular; Female; HIV Infecti | 2013 |
A pilot trial of pentoxifylline on endothelial function and inflammation in HIV-infected patients initiating antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Biomarkers; Endothelium, Vascular; Female; HIV Infecti | 2016 |
The use of pentoxifylline alone in HIV-infected patients.
Topics: CD4-Positive T-Lymphocytes; HIV; HIV Core Protein p24; HIV Infections; Humans; Leukocyte Count; Leuk | 1994 |
Pruritus in HIV-1 disease: therapy with drugs which may modulate the pattern of immune dysregulation.
Topics: Administration, Cutaneous; Administration, Topical; Anti-Inflammatory Agents; Antipruritics; Cycloox | 1997 |
Pentoxifylline in human immunodeficiency virus- positive tuberculosis: safety at 4 years.
Topics: AIDS-Related Opportunistic Infections; Follow-Up Studies; HIV Infections; Humans; Pentoxifylline; Re | 1998 |
Pentoxiphylline reduces nitric oxide production among patients with HIV infection.
Topics: Adult; Citrulline; Female; HIV Infections; Humans; Male; Middle Aged; Nitric Oxide; Nitrites; Pentox | 2000 |
9 other studies available for pentoxifylline and HIV Coinfection
| Article | Year |
|---|---|
Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study.
Topics: Adult; Anti-Inflammatory Agents; Brachial Artery; Endothelium, Vascular; Female; HIV Infections; Hum | 2010 |
Reduced apoptosis by pentoxiphylline among patients with HIV infection.
Topics: Adult; Apoptosis; Caspase 1; Caspase 8; Caspase 9; Caspases; CD4 Lymphocyte Count; Cell Survival; En | 2003 |
[No improvement of lipodystrophy syndrome in an HIV-infected patient].
Topics: Adult; Antiretroviral Therapy, Highly Active; HIV Infections; HIV-Associated Lipodystrophy Syndrome; | 2004 |
Pentoxifylline impairs macrophage defense against Mycobacterium avium complex.
Topics: CD4 Lymphocyte Count; Cells, Cultured; HIV Infections; HIV Seronegativity; Humans; Interleukin-6; Ma | 1995 |
Pentoxifylline: clinical application in human immunodeficiency virus-associated optic neuropathy.
Topics: HIV Infections; HIV-1; Humans; Optic Atrophies, Hereditary; Pentoxifylline | 1995 |
[Pentoxifylline and oral aphthosis in patients with HIV infection].
Topics: Adult; Female; HIV Infections; Humans; Male; Pentoxifylline; Stomatitis, Aphthous | 1997 |
Efficacy of pentoxifylline in the treatment of pruritic papular eruption of HIV-infected persons.
Topics: Adult; Female; HIV Infections; Humans; Interleukin-4; Male; Pentoxifylline; Pruritus; Skin Diseases, | 1998 |
[Improvement of severe psoriasis in a HIV(+) patient].
Topics: Adult; Female; HIV Infections; Humans; Pentoxifylline; Psoriasis; Recurrence; Stomatitis, Aphthous; | 2000 |
Suppression of beta 2 microglobulin by pentoxiphylline therapy in asymptomatic HIV infected individuals.
Topics: Adult; beta 2-Microglobulin; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Humans; M | 2001 |